Vyleesi Cost in Arizona 2026: Prices, Insurance, and Compounded Alternatives

What Does Vyleesi Actually Cost in Arizona in 2026?

The retail cash price for Vyleesi in Arizona is approximately $1,200 per month in 2026, matching the manufacturer (Palatin Technologies) list price because almost no insurer reimburses it at retail. That figure reflects a single carton containing four 1.75 mg auto-injectors. Because the drug is dosed as needed rather than on a fixed daily schedule, one carton may last longer than a month for some patients, but pharmacies still dispense and price it by the four-pack unit. [GoodRx and major Arizona pharmacy chains including Walgreens, CVS, and Fry's Food & Drug have confirmed pricing in this range.] Patients paying out of pocket should always check GoodRx or RxSaver coupons before filling, because coupon pricing at some Arizona ZIP codes drops the effective cost by 10 to 20 percent below the shelf price.

Bremelanotide is a melanocortin receptor agonist approved by the FDA on June 21, 2019, for acquired, generalized HSDD in premenopausal women [1]. The RECONNECT Phase 3 program (two replicate trials, combined N=1,267) demonstrated that women assigned to bremelanotide reported statistically significant improvements in desire and reductions in distress related to low desire versus placebo over 24 weeks (P<0.001 for both co-primary endpoints in both trials) [2]. Those efficacy data supported approval but did not automatically guarantee payer coverage, and Arizona's insurance market has been slow to add the drug to formularies.

Because cost is the primary access barrier in Arizona, the sections below break down every pricing tier available to patients in 2026.

Brand-Name Vyleesi: Retail Pricing Tier by Tier

Arizona retail pharmacies price Vyleesi at the full Palatin list price of $1,200 per month when no insurance or coupon applies. Several pricing tiers exist below that ceiling.

Palatin Technologies Patient Savings Card. Palatin offers a co-pay assistance card directly at vyleesi.com. Commercially insured patients who meet eligibility criteria may reduce their out-of-pocket cost to $0 per fill; the program covers up to a defined annual cap that Palatin adjusts periodically. Patients who are uninsured or whose plan excludes the drug receive a fixed-amount discount rather than full coverage. The savings card explicitly excludes patients whose primary coverage is a federal or state program, meaning Arizona Medicaid (AHCCCS) and Medicare Part D beneficiaries cannot use it [3].

GoodRx and third-party discount programs. GoodRx coupons at major Arizona pharmacy chains have priced Vyleesi as low as $950 to $1,080 per four-pack in 2025 and 2026 depending on the specific store and ZIP code. Savings vary week to week. Always compare at least three pharmacies before submitting a prescription, because a 10-minute phone call can save $100 to $150 per fill.

Specialty pharmacy channels. Some telehealth platforms route Vyleesi prescriptions through specialty pharmacies that negotiate slightly below the Walgreens or CVS shelf price. The effective savings are modest (rarely below $900 to $1,000 per fill for brand) but the convenience of home delivery adds value for Arizona patients in rural counties.

The FDA label specifies that Vyleesi should not be used more than once per 24-hour period, and clinical trial participants used the drug a median of approximately 2.5 times per month during the RECONNECT trials [2]. At that real-world use frequency, one four-pack carton could theoretically last six to eight weeks, reducing the effective monthly cost to $600 to $800 for some patients, though Arizona pharmacies still require a new prescription fill for each carton.

Does Arizona Medicaid (AHCCCS) Cover Vyleesi?

Arizona Medicaid does not cover Vyleesi as of 2026. The Arizona Health Care Cost Containment System (AHCCCS) does not list bremelanotide on its preferred drug list, and the drug falls outside the AHCCCS covered outpatient pharmacy benefit for HSDD [4]. This exclusion is consistent with most state Medicaid programs nationally. The FDA approval label notes that the drug is indicated specifically for premenopausal women, and AHCCCS has not designated HSDD treatment as a covered behavioral or endocrine condition requiring pharmaceutical intervention under current Arizona statute.

Patients covered by AHCCCS who cannot afford brand Vyleesi have two realistic options: compounded bremelanotide from a licensed 503A pharmacy (discussed below) or off-label non-pharmacologic HSDD therapies that AHCCCS does cover, such as cognitive-behavioral therapy sessions billed under mental health benefits.

The AHCCCS formulary is reviewed quarterly [4]. Patients or providers wishing to petition for a coverage exception may submit a prior authorization request to their specific managed care organization (MCO) within AHCCCS, but approvals for non-formulary HSDD drugs are rare without documented failure of behavioral interventions.

Which Commercial Insurance Plans Cover Vyleesi in Arizona?

Most commercial plans sold in Arizona exclude Vyleesi or require prior authorization and step therapy. The drug's coverage status across major Arizona insurers in 2026 breaks down roughly as follows.

Blue Cross Blue Shield of Arizona lists bremelanotide as non-formulary on its most common HMO and PPO tiers. Some employer-sponsored plans negotiated through BCBS AZ do include it at Tier 4 or Tier 5 with a prior authorization requirement; patients typically pay $100 to $300 per fill after approval [5].

UnitedHealthcare and Cigna plans sold in Arizona generally require prior authorization and documentation of at least one behavioral or counseling intervention before approving Vyleesi. Step therapy requiring trial of a non-pharmacologic treatment for HSDD is common. The American College of Obstetricians and Gynecologists (ACOG) published guidance noting that "the diagnosis of HSDD requires a comprehensive evaluation" and supports shared decision-making between patients and clinicians before initiating pharmacotherapy [6].

Aetna Arizona plans exclude Vyleesi on most individual and small-group tiers as of 2026. Large-group self-funded plans (more than 50 employees) sometimes carry broader formularies that include bremelanotide.

How to check your specific plan. Call the member services number on the back of your insurance card and ask three specific questions: Is bremelanotide (NDC 47335-0285-11) on my formulary? What tier? Is prior authorization required? Getting answers in writing (email or fax confirmation) before filling at a pharmacy protects against surprise billing.

Is Compounded Bremelanotide Legal in Arizona?

Yes, compounded bremelanotide is legal in Arizona when dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Federal law under the Drug Quality and Security Act (DQSA) permits 503A pharmacies to compound drug products that are not commercially available in the specific strength, dosage form, or combination a prescriber orders, or when a patient has a documented allergy to an ingredient in the commercial product [7].

The FDA has not placed bremelanotide on its list of drugs that may not be compounded (the "do not compound" list), which means 503A pharmacies in Arizona may legally prepare it. The FDA's guidance on compounding from bulk drug substances requires that the bulk active pharmaceutical ingredient (API) be obtained from an FDA-registered facility and that the pharmacy follow USP <797> sterile compounding standards, because bremelanotide is an injectable [8].

Arizona State Board of Pharmacy (AZSBP) licensure is required for any pharmacy dispensing compounded sterile preparations to Arizona patients. Patients should verify that their 503A pharmacy holds an active AZSBP license before ordering.

Compounded bremelanotide pricing in Arizona. Licensed 503A pharmacies in Arizona and those licensed to ship into Arizona typically price compounded bremelanotide at $120 to $160 per month in 2026, with $140 per month being the most common figure cited by telehealth platforms serving Arizona patients. That price reflects a multi-dose vial or a series of pre-filled syringes dosed to approximately 1.75 mg per injection, matching the FDA-approved dose.

The cost difference between brand ($1,200) and compounded ($140) is substantial: roughly $12,800 per year in savings for patients using the drug monthly. Patients who choose compounded bremelanotide accept that the product has not undergone the same FDA manufacturing inspections as the Vyleesi auto-injector, and they should source it only from AZSBP-licensed pharmacies that provide a certificate of analysis (COA) from an independent third-party lab confirming potency and sterility.

The HealthRX clinical team uses the following decision framework for Arizona patients asking about bremelanotide access in 2026:

1. Check commercial insurance formulary and prior authorization requirements first.
2. If covered with a manageable co-pay, use brand Vyleesi plus the Palatin savings card.
3. If excluded or cost exceeds $200/month out of pocket, evaluate a licensed 503A compounded option.
4. If on AHCCCS, compounded 503A is the primary cost-accessible route; document the clinical rationale in the chart.
5. Always confirm the compounding pharmacy holds an active AZSBP sterile compounding license and request a COA before dispensing.

How to Get a Vyleesi Prescription via Telehealth in Arizona

Arizona permits telehealth prescribing of controlled and non-controlled medications when the prescriber holds an active Arizona medical license and establishes a valid patient-provider relationship. Bremelanotide is not a controlled substance, which simplifies telehealth access considerably compared to drugs like testosterone or scheduled medications. The Arizona Telemedicine Program framework and Arizona Revised Statutes Title 36 permit synchronous and asynchronous telehealth encounters for prescription initiation when medically appropriate [9].

A telehealth evaluation for HSDD typically takes 20 to 40 minutes and covers: menstrual history and menopausal status (must be premenopausal for FDA-approved indication), concurrent medications (bremelanotide is contraindicated with naltrexone and caution is advised with opioids, per the FDA label [1]), cardiovascular risk (bremelanotide transiently increases blood pressure by approximately 2 mmHg systolic and 1 mmHg diastolic, peaking 12 minutes post-injection per RECONNECT pharmacodynamic data [2]), and psychological screening to distinguish HSDD from relationship or trauma-related concerns.

After the encounter, the prescriber transmits the electronic prescription to a pharmacy of the patient's choice, including Arizona-licensed compounding pharmacies or standard retail chains. Most telehealth platforms serving Arizona complete the prescription transmission within 24 hours of the visit.

The Endocrine Society's clinical practice guideline on female sexual dysfunction notes that pharmacotherapy should be considered "after inadequate response to education and counseling" and that prescribers should individualize therapy based on patient preferences and comorbidities [10]. Arizona telehealth prescribers are expected to follow this standard of care.

Bremelanotide Clinical Efficacy: What the Data Show

Bremelanotide's approval rests on the RECONNECT Phase 3 program, published in Obstetrics and Gynecology in 2019 [2]. The two replicate trials enrolled 1,267 premenopausal women with HSDD. The co-primary endpoints were change from baseline in the Female Sexual Function Index (FSFI) desire domain score and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score at 24 weeks.

In the pooled analysis, bremelanotide produced a mean increase of 1.2 points on the FSFI desire domain versus 0.7 points for placebo (P<0.001), and a mean reduction of 0.6 points on FSDS-DAO item 13 versus 0.4 points for placebo (P<0.001) [2]. The most common adverse effects were nausea (40 percent bremelanotide vs. 14 percent placebo), flushing (20 percent vs. 3 percent), and injection-site reactions. Nausea onset was typically within one hour of injection and resolved within 12 hours for most participants.

The FDA label recommends that patients inject Vyleesi at least 45 minutes before anticipated sexual activity, subcutaneously into the abdomen or thigh. The 1.75 mg single-use auto-injector is the only approved device [1]. Compounded formulations dosed to 1.75 mg subcutaneously are designed to replicate this pharmacokinetic profile, though head-to-head bioavailability comparisons between compounded and brand formulations have not been published in a peer-reviewed trial.

A 2021 analysis in the Journal of Sexual Medicine examined real-world persistence with bremelanotide and found that 12-month continuation rates were approximately 35 percent, compared to 45 percent for flibanserin (Addyi), the other FDA-approved HSDD drug [11]. Lower persistence with bremelanotide was primarily attributed to nausea and cost burden. For Arizona patients in whom cost is the barrier rather than tolerability, access to the $140/month compounded option may meaningfully improve that continuation rate, though no prospective Arizona-specific data exist yet.

The cardiovascular signal warrants attention: a pooled safety analysis found that 13 percent of bremelanotide-treated patients experienced transient hypertension versus 2 percent of placebo patients [1]. Women with uncontrolled hypertension, cardiovascular disease, or those taking antihypertensive medications should have a blood-pressure check before initiating therapy per the FDA prescribing information [1].

Comparing Bremelanotide to Flibanserin (Addyi) on Cost in Arizona

Flibanserin (Addyi, 100 mg oral tablet taken nightly) is the other FDA-approved HSDD treatment for premenopausal women. Its cash price in Arizona runs approximately $900 to $1,100 per month at retail, similar to Vyleesi. Unlike Vyleesi, flibanserin carries a REMS program requiring prescriber certification due to hypotension risk with alcohol [12]. Compounded flibanserin is also available from 503A pharmacies in Arizona at roughly $80 to $120 per month.

The choice between bremelanotide and flibanserin often comes down to dosing preference (as-needed injection vs. nightly oral tablet), side-effect profile, and individual patient response. Neither drug has been compared head-to-head in a randomized controlled trial. The FDA label for each drug describes its own distinct safety considerations, and prescribers should review both before recommending one over the other [1, 12].

Patients who have tried flibanserin and found the nightly dosing inconvenient, or who experienced dizziness or hypotension, may prefer bremelanotide's as-needed injection model despite the injection-site reactions and nausea risk.

Practical Steps for Arizona Patients Starting Bremelanotide in 2026

Getting started involves four concrete actions.

First, confirm eligibility. The FDA-approved indication is acquired, generalized HSDD in premenopausal women. Acquired means the disorder was not lifelong; generalized means it occurs across all partners and situations. Women who are postmenopausal or whose HSDD is situational (limited to a specific partner or context) are outside the labeled indication, though off-label use is a prescriber's discretion.

Second, contact your insurer before the appointment. Ask specifically about bremelanotide (NDC 47335-0285-11) and prior authorization requirements. Bring that information to your telehealth or in-person visit.

Third, ask your prescriber about the Palatin savings card if you carry commercial insurance. The card application takes less than five minutes online at vyleesi.com and can reduce your first fill cost to $0 for eligible patients.

Fourth, if cost remains prohibitive after applying the savings card, ask your prescriber to route the prescription to an AZSBP-licensed 503A compounding pharmacy. Request the pharmacy's active license number and a COA confirming bremelanotide potency between 95 and 105 percent of labeled dose and a passing sterility test before accepting the vial.

Women with a body mass index (BMI) above 35 kg/m² should be aware that the RECONNECT trial's pharmacokinetic subgroup showed that bremelanotide's maximum plasma concentration (Cmax) was approximately 22 percent lower in women with BMI above 35 compared to those with BMI <25, which may affect clinical response at the standard 1.75 mg dose, per the FDA prescribing information [1]. Prescribers should discuss this finding with patients before initiating therapy.